Publicaciones en las que colabora con Leire Arbea Moreno (27)

2023

  1. Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control

    Journal for immunotherapy of cancer, Vol. 11, Núm. 1

  2. Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma

    Pancreatology, Vol. 23, Núm. 4, pp. 411-419

2020

  1. Repeated stereotactic radiosurgery for recurrent brain metastases: An effective strategy to control intracranial oligometastatic disease

    Critical Reviews in Oncology/Hematology, Vol. 153

2019

  1. Erratum: Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience (PLoS ONE (2019)14:6 (e0217881)Doi:10.1371/journal.pone.0217881)

    PLoS ONE

  2. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience

    PLoS ONE, Vol. 14, Núm. 6

  3. Long-term results of Perioperative High Dose Rate Brachytherapy (PHDRB) and external beam radiation in adult patients with soft tissue sarcomas of the extremities and the superficial trunk: Final results of a prospective controlled study

    Radiotherapy and Oncology, Vol. 135, pp. 91-99

  4. Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse

    Cancers, Vol. 11, Núm. 5

2016

  1. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes

    Brachytherapy, Vol. 15, Núm. 2, pp. 127-135

  2. Multicatheter breast implant during breast conservative surgery: Novel approach to deliver accelerated partial breast irradiation

    Brachytherapy, Vol. 15, Núm. 4, pp. 485-494

  3. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer

    British Journal of Cancer, Vol. 115, Núm. 6, pp. 655-663

2015

  1. Salvage wide resection with intraoperative electron beam therapy or HDR brachytherapy in the management of isolated local recurrences of soft tissue sarcomas of the extremities and the superficial trunk

    Brachytherapy, Vol. 14, Núm. 1, pp. 62-70

  2. Time to loading and locoregional control in perioperative high-dose-rate brachytherapy: The tumor bed effect revisited

    Brachytherapy, Vol. 14, Núm. 4, pp. 565-570

2013

  1. Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy

    Journal of Translational Medicine, Vol. 11, Núm. 1

2012

  1. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: Preliminary data on clinical outcome

    International Journal of Radiation Oncology Biology Physics, Vol. 82, Núm. 3

  2. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: A validation phase II trial

    International Journal of Radiation Oncology Biology Physics, Vol. 83, Núm. 2, pp. 587-593

2011

  1. Determinants of complications and outcome in high-risk squamous cell head-and-neck cancer treated with perioperative high-dose rate brachytherapy (PHDRB)

    International Journal of Radiation Oncology Biology Physics, Vol. 81, Núm. 4

  2. Patterns of response after preoperative intensity-modulated radiation therapy and capecitabine/oxaliplatin in rectal cancer: Is there still a place for ecoendoscopic ultrasound?

    International Journal of Radiation Oncology Biology Physics, Vol. 81, Núm. 2, pp. 439-444

  3. Patterns of response after preoperative treatment in gastric cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 80, Núm. 3, pp. 698-704

2010

  1. A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer

    International Journal of Gynecological Cancer, Vol. 20, Núm. 1, pp. 133-140

  2. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: Comparison of two different schedules

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 33, Núm. 2, pp. 137-143